首页> 外文期刊>Urology >Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate.
【24h】

Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate.

机译:口服西地那非对前列腺癌放疗后勃起功能障碍患者的疗效。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To determine the efficacy of sildenafil for patients with erectile dysfunction after radiotherapy for localized prostate cancer. METHODS: Fifty patients with erectile dysfunction after radiotherapy were treated with sildenafil. Their median age was 68 years (range 54 to 78). All were treated with a three-dimensional conformal external beam radiotherapy approach, and the median dose prescribed to the planning target volume was 75.6 Gy. Patients were initially given 50 mg of sildenafil and instructed to use the medication on at least three occasions. They were then contacted to ascertain the efficacy of and tolerance to the medication. RESULTS: Significant improvement in the firmness of the erection after sildenafil was reported in 37 patients (74%), 2 (4%) had partial improvement, and 11 (22%) had no response. Significant improvement in the durability of the erection was reported in 33 patients (66%), 3 (6%) had partial improvement, and 14 (28%) reported no improvement. Patients with partial or moderate erectile function before using sildenafil were more likely to benefit from the medication compared with those with absent function. Among 29 patients with erections classified as partial after radiotherapy, 26 (90%) had a significant response to the medication. In contrast, only 11 (52%) of 21 with erections classified as flaccid after radiotherapy had a significant response to the medication (P = 0.007). CONCLUSIONS: Sildenafil improved erectile function in greater than two thirds of patients with postradiotherapy impotence. Patients with less severe dysfunction are most likely to benefit from this intervention.
机译:目的:确定西地那非对局部前列腺癌放疗后勃起功能障碍患者的疗效。方法:对50例放射治疗后的勃起功能障碍患者进行西地那非治疗。他们的中位年龄为68岁(范围为54至78)。所有患者均接受了三维共形外部束放射疗法,计划目标体积的中位剂量为75.6 Gy。最初给患者服用50毫克西地那非,并指示其至少在三种情况下使用该药物。然后联系他们以确定药物的功效和耐受性。结果:据报道,西地那非治疗后的勃起牢固度显着改善,其中37例(74%),2例(4%)部分改善,11例(22%)无反应。据报告33例患者(66%)勃起的持久性显着改善,其中3例(6%)有部分改善,14例(28%)没有改善。与没有功能的患者相比,使用西地那非之前具有部分或中度勃起功能的患者更可能受益于药物治疗。在29名放疗后分类为部分勃起的患者中,有26名(90%)对药物有明显反应。相反,在放疗后分类为松弛的21例勃起中,只有11例(52%)对药物有明显反应(P = 0.007)。结论:西地那非可改善放射治疗后阳imp患者三分之二以上的勃起功能。功能障碍较轻的患者最有可能从这种干预中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号